We aim to redefine treatment for retinal disease
Aiming to redefine treatment
AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, is in Phase 3 clinical trials for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR), aiming to improve long-term outcomes while reducing the frequency of injections
Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this website.
All investigational product candidates are currently undergoing clinical evaluation. This content is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval or other regulatory authority approval.
Wet AMD
AXPAXLI aims to treat patients with only 1-2 injections per year while maintaining disease control and preserving visual acuity
Initial Wet AMD Treatments
Up to 12 injections per year*
Current Wet AMD Treatments
Up to 6 injections per year*
Future Wet AMD Treatments
1-2 injections per year**
*Based on product prescribing information9 **Based on clinical trial designs
Diabetic Retinopathy
AXPAXLI seeks to unlock the diabetic market and treat the full spectrum of diabetic retinal disease
Each dot represents ~50,000 patients
Explore our clinical trials
References
1. Zhao Y, et al. Oncologist. 2015;20(6):660-673. 2. Gross-Goupil M, et al. Clin Med Insights Oncol. 2013;7:269-277. 3. Liang C, et al. Mol Ther Oncolytics. 2022;24:577-584. 4. Sawhney AS, et al., Inventors, Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US Patent 8,409,606 B2. April 2, 2013. 5. Blizzard C, et al. Clin Ophthalmol. 2021:15 2055–2061. 6. Boyer DS, et al. Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Related Macular Degeneration. Presented at: American Academy of Ophthalmology Annual Meeting; November 13-15, 2020; Virtual. 7. Goldstein MH, et al. Invest Ophthalmol Vis Sci. 2020;61(7):4266. 8. McGrath M, et al. Invest Ophthalmol Vis Sci. 2014;55:472. 9. Aziz AA, et al. Eye. 2025;39(6):1099-1106. 10. Market Scope. 2025 Exudative Retinal Disease Pharmaceuticals Market Report. St. Louis, MO: Market Scope, LLC. 2025. 11. Market Scope. Ophthalmic Market Trends: Quarterly US Retina Edition. St. Louis, MO: Market Scope, LLC. 2025.
